Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmo, Sweden on 23-24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms.


Chalmers, J. R. Simpson, E. Apfelbacher, C. J. Thomas, K. S. von Kobyletzki, L. Schmitt, J. Singh, J. A. Svensson, A. Williams, H. C. Abuabara, K. Aoki, V. Ardeleanu, M. Awici-Rasmussen, M. Barbarot, S. Berents, T. L. Block, J. Bragg, A. Burton, T. Bjerring Clemmensen, K. K. Creswell-Melville, A. Dinesen, M. Drucker, A. Eckert, L. Flohr, C. Garg, M. Gerbens, L. A. Graff, A. L. Hanifin, J. Heinl, D. Humphreys, R. Ishii, H. A. Kataoka, Y. Leshem, Y. A. Marquort, B. Massuel, M. A. Merhand, S. Mizutani, H. Murota, H. Murrell, D. F. Nakahara, T. Nasr, I. Nograles, K. Ohya, Y. Osterloh, I. Pander, J. Prinsen, C. Purkins, L. Ridd, M. Sach, T. Schuttelaar, M. L. Shindo, S. Smirnova, J. Sulzer, A. Synnove Gjerde, E. Takaoka, R. Vestby Talmo, H. Tauber, M. Torchet, F. Volke, A. Wahlgren, C. F. Weidinger, S. Weisshaar, E. Wollenberg, A. Yamaga, K. Zhao, C. Y. Spuls, P. I.


Journal: Br J Dermatol
Volume: 175
Issue: 1
Pages: 69 - 79
Year: 2016
DOI: 10.1111/bjd.14773

Further Study Information

Current Stage: Not Applicable
Date: April 2015
Funding source(s): All delegates covered their own travel and accommodation expenses with the exception of patients and representatives from patient groups. Costs for patients were met by either their national eczema patient association, a participating Harmonising Outcome Measures for Eczema (HOME) member or by a donation from a pharmaceutical company. H.W. supported the travel and accommodation costs for J.A.S. to attend as our independent advisor from the Outcome Measures in Rheumatology (OMERACT) group. The local organizers (Å.S. and L.v.K.) used an unrestricted educational grant from the LEO Foundation, plus contributions from the Swedish Asthma and Allergy Foundation and the County of Skåne, to support the local meeting arrangements. M.R. is funded by a National Institute for Health Research (NIHR) Post Doctoral Fellowship (PDF-2014-07-013) and T.S. is funded by a NIHR Career Development Fellowship (CDF-2014-07-006).

Health Area

Disease Category: Skin

Disease Name: Eczema

Target Population

Age Range: Unknown

Sex: Either

Nature of Intervention: Any

Stakeholders Involved

- Clinical experts
- Consumers (patients)
- Methodologists
- Patient/ support group representatives
- Pharmaceutical industry representatives

Study Type

- Recommendations for outcome measures (measurement/how)


- Consensus meeting

Linked Studies

Related Links

    No related links